Salute e Benessere

UGREEN Adds Two New Products to Its Nexode Power Bank Family for Ultimate…

Ideal for long-distance travelers, this high-capacity, high-wattage power bank is essential for outdoor adventures. Whether camping or hiking, users will stay powered and connected. It's also perfect for outdoor photographers and videographers, offering continuous power for action cameras. Ideal for long-distance travelers, this high-capacity, high-wattage power bank is essential for outdoor adventures. Whether camping or hiking, users will stay powered and connected. It's also perfect for...
PR Newswire
08/07/2024

A pill for infertility: Oxolife's non-hormonal oral drug raises embryo…

Today, Oxolife is presenting highly promising new data at ESHRE from its proof-of-concept Phase 2 double-blinded, randomised controlled trial of OXO-001, in which it was tested against a placebo pill. Today, Oxolife is presenting highly promising new data at ESHRE from its proof-of-concept Phase 2 double-blinded, randomised controlled trial of OXO-001, in which it was tested against a placebo pill. An exploratory subset analysing 96 women up to 40 years of age, who all underwent single...
PR Newswire
08/07/2024

New4med GmbH Announces First Cases of its novel Basivertebral Nerve Ablation…

BVNA is a treatment for vertebrogenic pain, a type of chronic low back pain associated with bony lesions on the vertebral endplates. The system, approved inEurope, is a minimally invasive, implant-free procedure that can be performed on both inpatient and outpatient bases. It uses targeted radiofrequency energy to block the Nervus basivertebralis from transmitting pain signals to the brain, aiming to improve function and provide sustainable relief. "By offering BVNA to physicians,...
PR Newswire
08/07/2024

SmartCella raises EUR 50 million to accelerate growth and commercialization

The capital raise was supported by existing large institutional investors Fjärde AP-fonden, AMF Pension, and SEB-Stiftelsen, and also included new investors such as AstraZeneca, Handelsbanken Fonder and RoosGruppen AB. Christian Kinch and Thomas von Koch remain major shareholders (via SWIB Holding AB). The capital raise is part of the overall strategic development and future-proofing of SmartCella which includes continued investments in the organization and infrastructure as well as increased…
PR Newswire
08/07/2024

Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx…

Michael Bauer, Partner, Venture Investments, Novo Holdings said: "Myricx has gained unique insights into the biology of NMT and its orthogonal and differentiated mechanism. The scientific rationale behind its novel payload chemistry gives us confidence that NMTi ADCs have the potential to greatly expand the current repertoire of ADC applications beyond the current standard-of-care payload classes, creating opportunities for new treatment options for patients. This investment reflects our…
PR Newswire
08/07/2024

VIRBAC announces executive management changes

Sébastien Huron leaves the company, Habib Ramdani takes over while the Group recruits its next chief executive officer Virbac announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to...
Nasdaq GlobeNewswire
08/07/2024

VIRBAC: exceptional first-half growth and guidance raised for 2024

Compte tenu de ladynamique très positive de nos ventes observée sur le premier semestre(croissance du chiffre d'affaires attendue autour de 16% à taux de change constants 1et ~11% à taux de change et périmètre constants) qui devrait se poursuivre sur le second semestre, ainsi que d'un marché de la santé animale particulièrement porteur,la croissance du chiffre d'affaires 2024 à taux de change constants est attendue entre 12,5% et 14,5% 1(correspondant à une croissance désormais...
Nasdaq GlobeNewswire
08/07/2024

SKF Half-year report to be published on 18 July

To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers. To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers. Link to web event:https://www.investis-live.com/skf/66588e187e7bb30d00b5800f/haewt All information regarding the results will be made available on the Group's IR website:https://investors.skf.com/en/quarterly-reports Media: To book interviews withRickard...
PR Newswire
08/07/2024

Strengthened presence in Europe

Press release Ecully, July 8, 2024 – 8 a.m. Spineway continues its sales and marketing efforts in Europe The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it participated in the38th edition of GEER, the annual congress of the Spanish Spine Society, held in Malaga in May.GEER is the annual meeting of spine surgeons in Spain, like theSFCR Congressheld in Montpellier at the beginning of June. 1...
Nasdaq GlobeNewswire
08/07/2024

Memo Therapeutics AG appoints Paul Carter as Chairperson

PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8July, 2024 – Memo Therapeutics AG(or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to...
Nasdaq GlobeNewswire
08/07/2024

AB Science announces positive results of its Phase 2 study evaluating masitinib…

PRESS RELEASEAB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19Paris, 8 July 2024, 8am CETAB Science SA(Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19.This randomized (1:1), open-label, phase 2 study (AB20001) was designed to evaluate the safety and efficacy of masitinib plus isoquercetin in hospitalized patients with moderate COVID-19 (WHO 7-point ordinal scale level 4) or...
Nasdaq GlobeNewswire
08/07/2024

ESHRE 40th Annual Meeting: Air pollution linked to a decrease in IVF birth rate…

Conducted over an eight-year period in Perth, Australia, the research analysed 3,659 frozen embryo transfers from 1,836 patients. The study examined air pollutant concentrations over four exposure periods prior to oocyte retrieval (24 hours, 2 weeks, 4 weeks, and 3 months), with models created to account for co-exposures. Conducted over an eight-year period inPerth, Australia, the research analysed 3,659 frozen embryo transfers from 1,836 patients. The study examined air pollutant...
PR Newswire
08/07/2024

Hainan Free Trade Port deepens cooperation with Switzerland

During their time in Switzerland, the Hainan delegation held discussions and research meetings with numerous important companies and institutions, including Merck, Richemont, Roche Diagnostics, EHL Hospitality Business School, Switzerland Global Enterprise, the World Trade Organization, and the World Intellectual Property Organization. During their time inSwitzerland, theHainandelegation held discussions and research meetings with numerous important companies and institutions, including...
PR Newswire
07/07/2024

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)PARIS, July05, 2024(GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 06/30/2024100,093,63588,029,364 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,media@cellectis.com ...
Nasdaq GlobeNewswire
05/07/2024

Inventiva provides an update on its NATiV3 clinical program evaluating…

Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a patient profile similar to patients randomized in the NATIVE Phase IIb clinical trial.A blinded analysis of all randomized patients suggests weight gain plateaus and stabilizes between week 24 and 36...
Nasdaq GlobeNewswire
05/07/2024

Virbac : Declaration of the number of shares and voting rights 06/2024

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsJune, 30 20248 458 000Gross total of voting rights :...
Nasdaq GlobeNewswire
05/07/2024

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARESGhent, Belgium, 5 July 2024 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of (i) a subscription to new shares by certain non-executive independent directors pursuant to the "restricted share unit" or "RSU" plan as…
Nasdaq GlobeNewswire
05/07/2024

Global Contrast Media Injectors Market to Reach USD 2.3 billion by 2029 driven…

Browse in-depth TOC on "Contrast Media Injectors Market" Browse in-depth TOC on "Contrast Media Injectors Market" 180 - Tables50 - Figures206 - Pages Key Players in the Contrast Media Injectors Market: A Competitive Landscape The contrast media injectors market is consolidated, with key players adopting strategies such as partnerships, acquisitions, and expansions to maintain their market positions. As of 2023, the major players in this market include Bayer AG (...
PR Newswire
05/07/2024

RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC an affiliate of K1…

MANHATTAN BEACH, Calif., July 5, 2024 /PRNewswire/ -- On 24 May 2024, Meridian Bidco LLC ("Bidco") made an offer to acquire the entire issued and to be issued share capital of MariaDB plc ("MariaDB") (the "Offer") with the terms and conditions of the Offer set out in the offer document despatched and filed by Bidco as Exhibit (a)(1)(A) to the Tender Offer Statement and Rule 13e-3 Transaction Statement filed on Schedule TO with the US Securities and Exchange…
PR Newswire
05/07/2024

IM Cannabis Announces Intention to Complete Consolidation

After giving effect to the Consolidation, the Common Shares will be reduced from 13,394,136 to 2,232,357 Common Shares. No fractional Common Shares will be issued in connection with the Consolidation. Instead, all fractional Common Shares equal to or greater than one-half resulting from the Consolidation will be rounded to the next whole number, otherwise, the fractional Common Share will be cancelled. The exercise price and/or conversion price and number of Common Shares issuable under any of…
PR Newswire
05/07/2024

Zhiyi Biotech Successfully Completes Phase I Clinical Trial of SK10 for the…

This promising result lays the foundation for SK10 as a potential novel drug for CID patients. This promising result lays the foundation for SK10 as a potential novel drug for CID patients. About SK10: SK10, the firstBacteroides fragilis -based LBP obtained FDA IND approval, is also the first LBP of Next-generation probiotics developed by Chinese biotech company that approved for clinical trials by FDA. Studies have shown that SK10 can ameliorate 5-FU induced injury via mitochondrial...
PR Newswire
05/07/2024

XIAOHONGSHU Shines at VOGUE Business Global Beauty Summit

The summit featured Chujing, Head of Personal Care Department at XIAOHONGSHU, alongside over 100 global brand executives and marketing specialists from prestigious international companies such as LVMH Beauty, Kering Beauty, Estée Lauder, L'Oréal, P&G, Unilever, and Coty. Together, they discussed strategies to tap into and leverage local markets in the face of global trends, sparking new inspirations in BPC solutions and driving the global growth of brands. The summit featured Chujing, Head…
PR Newswire
05/07/2024

MAGic™ BioProcessing Secures Patent in USA and China

MAGic™ BioProcessing remains committed to advancing the field of separation technology and delivering innovative solutions that address the evolving needs of bio manufacturing. With this patented technology, MAGic™ BioProcessing is poised to revolutionize separation processes, driving efficiency, and enabling new processes in biotechnology and beyond. MAGic™ BioProcessing remains committed to advancing the field of separation technology and delivering innovative solutions that address the...
PR Newswire
05/07/2024

Long-time collaborators Botond Roska and José-Alain Sahel win the Wolf Prize…

Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy.The Wolf Prize, considered one of the most prestigious international awards, recognizes outstanding achievements in various fields including medicine. Roska, Director at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Professor at the University of Basel, and Sahel, Chair of Ophthalmology at the...
Nasdaq GlobeNewswire
05/07/2024
Altri  Comunicati